1344 Summer Street
Tel: 902-442-4655 ext 5551
About Appili Therapeutics
Appili Therapeutics is developing novel approaches to lead the fight against infectious disease. Despite numerous achievements in the development of anti-infectives, infectious disease remains the leading cause of death worldwide. Many pathogens are becoming increasingly resistant to standard anti-infectives, making treatment difficult or even impossible. The emergence and spread of deadly viruses and antimicrobial resistant bacteria and parasites remain critical threats to human health.
CEO: Kevin Sullivan, MBA
CFO: Kimberly Stephens
VP, Drug Development: Jamie Doran MSc, DABT, ERT
VP, Business Development: Sean McBride
Please click here for Appili Therapeutics' pipeline.
29 articles with Appili Therapeutics
Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, announced the voting results from its annual and special meeting of shareholders held on Thursday, September 26, 2019.
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it has retained BND Projects Inc. (“BND”) to provide strategic investor relations services.
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today reported its financial and operational results for the first quarter of its fiscal year 2020, which ended June 30, 2019.
Researchers to Present New Data on Appili Therapeutics Infectious Disease Programs at the 2019 Military Health System Research Symposium
ATI-1701 data demonstrate safety and efficacy of the Francisella tularensis vaccine candidate in preclinical studies and support ongoing accelerated development under FDA’s ‘Animal Rule’
7/3/2019Companies from across the globe provide information on agreements and pipeline updates.
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced its financial and operational results for the year ended March 31, 2019.
Appili Therapeutics Signs $3M USD Grant Contract with the United States Department of Defense to Develop Antibiotics that Target Superbugs
Appili’s multi-drug resistant antibiotic program has the potential to address public health threats for both military and civilian populations worldwide
Appili Therapeutics Receives Government of Canada Assistance to Support Continued Growth of its Novel Anti-Infective Pipeline
Pharmaceutical company Appili Therapeutics Inc. announced that it is receiving a $476,000 CAD repayable contribution through the Atlantic Canada Opportunities Agency’s Regional Economic Growth through Innovation program.
Appili Therapeutics Inc. announced today that it will participate in the Bloom Burton & Co.
Appili Therapeutics Announces Closing of $3.6 Million Special Warrant Private Placement and Filing of Preliminary Prospectus
- Appili Therapeutics Inc. ("Appili" or the "Company") is pleased to announce the closing of its private placement offering (the "Brokered Offering") of special warrants (the "Special Warrants") for aggregate gross proceeds of $1,944,282
Appili Therapeutics Appoints Seasoned Infectious Disease Global Drug Development Executive Dr. Theresa Matkovits to Its Board of Directors
ContraVir Pharmaceuticals COO Brings Extensive Infectious Disease-focused Drug Development Experience to Appili’s Board
10/8/2018Transition continues as biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those transitions.
Appili Therapeutics Appoints Veteran Drug Development Executive, Dr. Armand Balboni, as Its Inaugural Chief Scientific Officer
Appili Therapeutics Inc. has named Dr. Armand Balboni as its first Chief Scientific Officer (CSO).
At the Meeting, the shareholders re-elected individuals to serve on the Board of Directors until the next annual meeting of shareholders
Appili Therapeutics Completes Phase 1 Study for ATI-1501, Its Taste-Masked Oral Metronidazole Suspension, Demonstrating Significant Improvements in Taste and Palatability
New Antibiotic Formulation Designed to Treat Parasitic and Anaerobic Bacterial Infections; Appili Will Use Study Data as Basis for NDA Filing
Appili Therapeutics Inc. announced today that it will present at the 2018 Atlantic Venture Forum Technology Showcase.
Appili Therapeutics Raises an Additional $4.3 Million in Oversubscribed Financing to Advance its Anti-infective Pipeline
Appili Therapeutics today it raised an additional $4,339,000 in an oversubscribed private placement financing, bringing the total equity raised since its seed round in March 2016 to $11,816,000.
Appili Therapeutics announced today it has signed a licence agreement with the National Research Council of Canada (NRC) to develop ATI-1701, a vaccine to protect against Francisella tularensis, a potential bioterrorism agent that causes tularemia.
Mr. Mortimer is a seasoned biotechnology executive with proven abilities in leading capital market transactions. He will serve as chair of Appili’s audit committee.
Appili Therapeutics Receives $1.2M USD From the Department of Defense to Advance Antibiotic Targeting Drug-Resistant Bacteria
Appili will use the funds to develop a lead compound as a preclinical candidate for its ATI-1503 antibiotic program targeting drug-resistant, Gram-negative bacteria.